Ikarian Capital’s Bristol-Myers Squibb BMY Stock Holding History

Ikarian Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-300,000	Closed	-$18.1M	–	237
2020 Q3	$18.1M	Buy	+300,000	New	+$18.1M	1.31%	19

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ikarian Capital's BMY Position: Q1 2021 in Review

Ikarian Capital sold out of Bristol-Myers Squibb (BMY) in Q1 2021, closing a stake of 288,400 shares — an estimated $17.9M sold.

Ikarian Capital first reported a position in BMY in Q3 2020 and held it in 2 quarters. The position peaked at $17.9M in Q4 2020. 2,368 funds tracked by Wall St. Rank hold BMY as of Q1 2021.

Ikarian Capital reported no remaining Bristol-Myers Squibb position as of Q1 2021 after selling out during the quarter.
Ikarian Capital sold 288,400 Bristol-Myers Squibb shares in Q1 2021, an estimated $17.9M.
Ikarian Capital first reported a position in Bristol-Myers Squibb in Q3 2020 and held it in 2 quarters.
Ikarian Capital's Bristol-Myers Squibb position peaked at $17.9M in Q4 2020.
2,368 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2021.

Based on Ikarian Capital's 13F filing for Q1 2021, filed 17 May 2021.